AstraZeneca to buy Alexion for $39 billion to expand in immunology
December 12, 2020 at 09:21 AM EST
Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases.